Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370199 · ClinicalTrials.gov registry record · NA
Peripheral Blood Flow Responses to Electromagnetic Energy
A NA study of Exposure to Man-made Visible Light, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02370199 is a NA study of Exposure to Man-made Visible Light that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02370199, a NA study of Exposure to Man-made Visible Light, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.
Conditions Studied
Interventions
- DEVICE 670 nm light
- DRUG octafluropropane
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-11 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370199
The ClinicalTrials.gov registry entry for NCT02370199 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Exposure to Man-made Visible Light appearing as the primary indexed condition, and to 2 interventions - of which 670 nm light is the first listed.
NCT02370199 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02370199 about?
NCT02370199 is a clinical study titled "Peripheral Blood Flow Responses to Electromagnetic Energy". This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.
What is the current status of trial NCT02370199?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2014-11. Estimated completion is 2027-12-31.
What conditions does trial NCT02370199 study?
This clinical trial studies the following conditions: Exposure to Man-made Visible Light.
What interventions are being tested in trial NCT02370199?
The interventions under investigation include: 670 nm light (DEVICE), octafluropropane (DRUG).
Who is sponsoring clinical trial NCT02370199?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02370199 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.